Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

HIV-1 elicits vigorous humoral and cell-mediated responses: these fail to clear the infection but contain viral replication for several years, at the expense of ongoing immune activation and CD4+ T cell loss. Over the past 25 years, several mechanisms by which HIV-1 and other AIDS viruses evade host immune responses have been elucidated. Genetic variability, rapid establishment of a reservoir of latently-infected long-lived CD4+ T cells and resistance to neutralization by antibodies are formidable obstacles to the development of a preventive vaccine. This has been highlighted by the disappointing results of recent efficacy trials. However, this remains an urgent priority, as available prevention strategies have been insufficient to stop the global epidemic. Rare individuals who show no signs of progression after one or two decades of infection indicate that immune control of HIV-1 is possible and may inform vaccine design. © 2009 Elsevier Ltd. All rights reserved.

Original publication




Journal article



Publication Date





321 - 325